Moreover, the negative regulation of PD-1 by RORγ agonists is long lasting as RORγ-agonist-treated cells maintain reduced levels of PD-1 after repeated re-stimulation in the absence of an agonist compound and after being transferred into tumor-bearing mice, suggesting that the RORγ agonist may induce epigenetic changes in the PD-1 locus. The gene discussed is RORC; the disease is neoplasm.